We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Caldera is a heat battery company that seeks to institutionalise zero-carbon energy solutions for the masses. Its patented breakthrough, Warmstone heat battery, can store 100kWh of heat for a standard home for 24 hours. Caldera asserts that it takes renewable energy using a flexible green tariff with prices as low as 5p/kWh and stores it as heat, providing carbon-free hot water and heating via Warmstone. The company has raised over £1.5 million through grants and investment to date, installed its first pilot Warmstone product in a family home, established a manufacturing and R&D base, and acquired the support of an energy think tank, Energy Systems Catapult. It aspires to become a contender in the estimated £3.5 billion renewable energy storage market in the European Union (EU). The company is working with König Metall to build and sell Warmstone units via approved UK installers. Caldera will use the investment to install a small number of pilot units in trial homes in 2021 before a full commercial rollout in 2022.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,572,524
Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.
days to go: Expired investment: £357,179
An end-to-end digital platform providing aesthetic medical treatment in a market valued at almost £76bn. NowMe work closely with customers throughout the process by discussing the treatment they desire, selecting an appropriate medical practitioner from a UK Clinic and offering available finance solutions. The company is raising funds to refine their product and secure IP, as well as cover working capital requirements. The firm plan to launch in 2018 and by 2025 achieve international leadership.
days to go: Expired investment: £172,790
An innovation event that displays the greatest in medical healthcare technologies within exhibitions, conferences and workshops. GIANT Health has over 2000 delegates registered, with 235 speakers and 33 exhibitors whilst being sponsored by 8 global companies. Current revenue streams consist of event ticket sales, partnership packages, stage demos, etc. Events are held across Europe, with international expansion in the next phase.
days to go: Expired investment: £62,770
VPS work with vehicle manufacturers to provide labour such as fitting air conditioning, leather seats, etc. to their cars as they arrive at port from overseas. VPS's main focus is the manufacturing of Number Plates within the Approved British Standard and selling these directly to the car manufacturers.

Pitch Rated

62%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £851,620
Lightpoint Medical is a technology company that is a pioneer in developing and marketing precision-guided cancer surgery. Surgeons aren't able to see if the cancerous tissue has been removed in its entirety or not during a surgery. To better this situation, the company has developed an imaging technology based on PET radiopharmaceuticals, more precisely, Cerenkov Luminescence Imaging (CLI), which helps surgeons to detect cancer in a real-time during surgery. The company's first product has received marketing authorisation, i.e., the CE (European Conformity) Mark. A second product, a laparoscopic device for prostate cancer is in development. A non-clinical device has also been released. For its efforts, Lightpoint Medical won the 'Best in Show' Award at the 2014 MedTech Investing Europe Conference. The company aims to utilise the investment to scale its business.
days to go: Expired investment: Withheld
United Medicine have created a platform where experience, knowledge and opinion of their medical users is used to provide a global consensus and allows the good evidence to be separated from the bad.   
days to go: Expired investment: £152,000
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
Please watch the video for more information
days to go: Expired investment: £376,618
MGN Builders Merchants is a well-established, profitable, and a fast-growing builders merchants and skip hire based in London and Essex. It offers same or next day delivery on thousands of building products kept in stock at all times. Having served 50,000+ customers in 2018 (81k EBITDA), the company's client base includes small to medium-sized companies, private developers and DIY customers. In the last three years, the company has trebled its revenue from £2.5m in 2016 to £7m by January 2019, achieving an almost 100% sales increase YoY. MGN is raising funding to accelerate its rapid growth plans, expand its team, start selling online, and launch concrete delivery service to capture UK's £34bn construction supplied wholesale market.
days to go: Expired investment: £114,260
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph